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Advances in multimodal immunotherapy have signifi-
cantly reduced acute rejection rates and substantially
improved 1-year graft survival following renal trans-
plantation. However, long-term (10-year) survival rates
have stagnated over the past decade. Recent studies
indicate that antibody-mediated rejection (ABMR) is
among themost important barriers to improving long-
term outcomes. Improved understanding of the roles
of acute and chronic ABMR has evolved in recent years
following major progress in the technical ability to
detect and quantify recipient anti-HLA antibody pro-
duction. Additionally, new knowledge of the immu-
nobiology of B cells and plasma cells that pertains to
allograft rejection and tolerance has emerged. Still,
questions regarding the classification of ABMR, the
precision of diagnostic approaches, and the efficacy of
various strategies for managing affected patients
abound. This review article provides an overview of
current thinking and research surrounding the patho-
physiology and diagnosis of ABMR, ABMR-related
outcomes, ABMR prevention and treatment, as well
as possible future directions in treatment.
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Introduction
The widespread use of potent and specific immunosup-
pressive agents has significantly reduced acute cellular
rejection rates and substantially improved 1-year graft
survival following renal transplantation. Substantial im-
provement of long-term (10-year) outcomes, however, has
not been realized (1–4). A recent analysis of more than
250000North American renal transplant recipients showed
that despite modest improvements in long-term graft
survival between 1989 and 2005 (5), and improvements
in graft half-life in the past decade for both living and
deceased donor transplants (6), high attrition rates persist
that stubbornly limit recent progress (5).
The ongoing therapeutic challenge is to achieve effective
and safe immunosuppression and avoid unwanted tox-
icities to produce enduring renal allograft function (7–9). The
incidence of hyperacute rejection caused by preexisting
anti-HLA donor-specific antibodies (DSA) has been nearly
eliminated by crossmatch and compatibility matching
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strategies. Similarly, the incidence of acute T cell–mediated
injury has been significantly reduced with the effective
multimodal application of immunosuppressive agents.
However, acute and chronic antibody-mediated rejection
(ABMR) are playing an increasingly critical role in kidney
allograft loss and are considered among themost important
barriers that limit long-term outcomes (10–14).
Although the cellular and molecular pathways that regulate
ABMR are still under investigation, new knowledge of
humoral immunobiology indicate that B cell and plasma cell
activation results in the generation of DSA, which bind to
HLA or non-HLA molecules on the endothelium (15,16).
Antibody binding to endothelium and subsequent cellular
activation involving complement-dependent and -indepen-
dent pathways leads to the recruitment of natural killer (NK)
cells, polymorphonuclear neutrophils and macrophages,
which contribute to capillaritis and eventual tissue injury
(Figure 1) (15–17). The morphologic nature of endothelial
cell injury in acute ABMR demonstrates platelet aggrega-
tion, thrombotic microangiopathy (TMA) and neutrophilic
accumulation, resulting in an early pattern of cellular
necrosis and a relatively rapid decline in allograft function.
Chronic ABMR results from a repetitive pattern of chronic
thrombotic events and inflammatory changes, which result
in cellular injury and repair. It manifests as late transplant
glomerulopathy (TG) and results in a decline in renal
function (18). In addition to pathology mediated directly by
antibodies, recent evidence suggests that B cells and
plasma cells may themselves influence rejection or
tolerance (19,20). The clinical picture of ABMR has become
increasingly complex, with questions abounding regarding
its classification, the precision of diagnostic approaches,
and the efficacy of various therapeutic strategies for safely
and effectively managing affected patients (21). This article
provides an overview of current progress in clinical and
translational research surrounding ABMR pathophysiology
and ABMR-related outcomes, prevention, treatment and
future directions.
Defining and diagnosing ABMR
The first description of acute ABMR identified two distinct
features: neutrophils in peritubular capillaries (PTCs) and
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Figure 1: Mechanisms of donor-specific antibody-mediated endothelial injury in renal allografts. Anti-MHC antibodies may either
result in direct injury to the capillary endothelium or in indirect injury via complement fixation or recruitment of inflammatory cells with Fc
receptors. In cases with donor-specific antibodies that lack C4d deposition, endothelial injury and cellular recruitment could be important
mediators. Poly, polymorphonuclear cell. Reproduced with permission from Farkash and Colvin (15).
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de novo antidonor HLA class I antibodies (22,23). Around
the same time, C4d, a degradation product of the
complement pathway that binds covalently to the endothe-
lium, was identified as a stablemarker of antidonor humoral
activity (24). Subsequently, the correlation between DSA,
histologic findings of microcapillary injury and diffuse
(>50%) C4d deposits in the PTCs were described in acute
ABMR (25). C4d and DSA were also linked to the
histopathologic features of chronic ABMR (26,27). Since
2003, the Banff Working Group classification system for
renal allograft biopsies has differentiated T cell–mediated
rejection (TCMR) from ABMR (28,29). The most recent
Banff 2013 diagnosis of ABMR, published in this issue of
the journal, requires histologic evidence of acute or chronic
tissue injury, evidence of current/recent antibody interac-
tion with vascular endothelium and serologic evidence of
the presence of circulating DSA (30). Importantly, C4d
staining is no longer a requirement for the diagnosis of
ABMR (Table 1).
C4d and the diagnosis of ABMR
C4d is a split product of C4 activation and has no known
biological action. It may be activated by the classical and
lectin complement pathways and serves as a footprint of
antibody–antigen interactions on the surface of endothelial
cells (31). Although useful, C4d has significant limitations
for the diagnosis of ABMR, not least because of
methodological issues (immunoperoxidase vs. immunoflu-
orescence, frozen vs. paraffin), poor understanding of the
meaning of minimal and focal staining, and its waxing and
waning deposition. Staining depends on the density of the
capillary network, with poor sensitivity in chronic settings,
andC4d positivity has been reported in the absence of other
evidence of graft injury (21). Furthermore, C4d stainingmay
not be associated with measurable DSA in the case of non-
HLA antibodies or antibodies absorbed by the allograft (31).
Overall, the sensitivity of C4d is low, and its expression
depends on the density of PTCs. In this regard, a number of
studies have established the concept of C4d-negative acute
and chronic ABMR (32–35). Loupy et al (33) reported that
C4d staining waxed and waned and was not a sensitive
indicator of parenchymal disease in the first year after
transplant. In this study, 55%of C4d-negative biopsieswith
ABMR had evidence of concomitant capillary inflamma-
tion (33). Sis et al described that 60% of kidneys with high
endothelial activation and injury transcripts (ENDATs) and
chronic ABMR or graft loss were C4d negative (34).
Findings were confirmed by another study in which 63%
of late kidney failures after biopsy were attributable to
ABMR, but many were C4d negative (35). A recent
microarray study from Sellare´s et al (36) concluded that
changes in ABMR-associated gene expression (mostly in
endothelial or NK cells) correlated with the presence of
capillary lesions or DSA and may predict graft failure
independent of C4d staining. Together, these observations
point to the low sensitivity of C4d for the diagnosis of
humoral rejection and support the addition of novel
biomarkers of capillary inflammation and endothelial injury,
including NK cells and macrophages to the diagnosis
algorithm of ABMR (33–38). This recommendation was
officially acknowledged at the 11th Banff Conference on
Allograft Pathology (Figure 2) (21) andwas incorporated into
the new Banff 2013 diagnostic criteria for ABMR (30)
(Table 1).
DSA and the diagnosis of ABMR
Terasaki et al identified HLA antibodies in the serum of
patients after transplantation nearly 45 years ago (39).
However, the importance of a low-strength antibody that is
undetectable by cell-based methodology was not recog-
nized until studies from the same group, three decades
later, discovered a strong association between HLA anti-
bodies detected by solid-phase assays and graft failure (40).
DSA may be directed against HLA or other endothelial cell
antigens, and its presence is required for the diagnosis of
acute and chronic active ABMR (21,37,41). In addition,
there is growing evidence supporting the roles of
preformed and de novo DSA as independent risk factors
for acute and chronic ABMR and graft loss (14,41–51). A
recent systematic review and meta-analysis demonstrated
that the presence of DSA before transplantation was
associatedwith a twofold greater risk of acute rejection and
a 75% greater risk of graft loss (46). Despite these findings,
our understanding of the biological relevance of DSA
remains limited. In vitro studies suggest that anti-HLA class
I alloantibodies result in endothelial cell injury and activation
through both complement-dependent and complement-
independent pathways (52,53). However, little is known
about signal transduction in response to class II antibodies
or the pathogenesis of DSA-induced renal allograft injury in
actual patients. It is important to note that not all DSA fix
complement or cause ABMR and, conversely, not all
episodes of acute graft injury with capillary inflammation
and C4d deposition are associated with DSA being
detectable with standard assays. In fact, the majority of
patients with DSA maintain normal kidney function for
years and have long-term outcomes similar to nonsensi-
tized patients (14,42,48).
Another important limitation is that currently available HLA
antibody tests are qualitative and have not been cleared by
the US Food and Drug Administration (FDA) for quantitative
measurements (54). More studies are needed to identify
risk stratification strategies on the basis of semiquantitative
measures of DSA and calculated panel reactive antibody
(PRA), subclasses of immunoglobulin G anti-HLA anti-
bodies, and C1q complement-fixing DSA (44,55,56). Pend-
ing the results of collaborative standardization studies (57),
consensus guidelines on the testing and clinical manage-
ment issues associated with HLA and non-HLA antibodies
in transplantation were recently published (58). These
recommendations are intended to provide guidance on the
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use and clinical application of contemporary methods for
HLA antibody detection.
ABMR classification and phenotypes
The2011Banffmeeting report and a 2010workshop held by
the FDA both noted the confusion generated by reports on
acute and chronic ABMR, and emphasized the importance
of correctly defining ABMRphenotypes (21,54). In theBanff
report, two principal phenotypes of acute ABMR were
defined: (1) ABMR phenotype 1 in the presensitized patient,
occurring early posttransplant; and (2) ABMR phenotype 2,
which develops from the emergence of de novo DSA in the
late posttransplant period and is thought to be mostly
related to nonadherence or inadequate immunosuppres-
sion (12,59,60). However, additional characteristics—
including the nature of the antibody; the significance of
C4d; the severity of microcapillary injury, gene transcripts,
Table 1: Revised (Banff 2013) classification of antibody-mediated rejection (ABMR) (30)
Acute/active ABMR; all three features must be present for diagnosis1,2
1. Histologic evidence of acute tissue injury, including one or more of the following:
 Microvascular inflammation (g>03 and/or ptc>0)
 Intimal or transmural arteritis (v>0)4
 Acute thrombotic microangiopathy (TMA), in the absence of any other cause
 Acute tubular injury, in the absence of any other apparent cause
2. Evidence of current/recent antibody interaction with vascular endothelium, including at least one of the following:
 Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections, or C4d>0 by IHC on paraffin sections)
 At least moderate microvascular inflammation ([gþptc]2)5
 Increased expression of endothelial activation and injury transcripts (ENDATs) or other gene expression markers of endothelial
injury in the biopsy tissue, if thoroughly validated
3. Serologic evidence of donor-specific antibodies (HLA or other antigens)
Chronic, active ABMR; all three features must be present for diagnosis1,6
1. Morphologic evidence of chronic tissue injury, including one or more of the following:
 Transplant glomerulopathy (cg>0),7 if no evidence of chronic TMA
 Severe peritubular capillary basement membrane multilayering (requires electron microscopy [EM])8
 Arterial intimal fibrosis of new onset, excluding other causes9
2. Evidence of current/recent antibody interaction with vascular endothelium, including at least one of the following:
 Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections, or C4d>0 by IHC on paraffin sections)
 At least moderate microvascular inflammation ([gþptc]2)5
 Increased expression of endothelial activation and injury transcripts (ENDATs) or other gene expression markers of endothelial
injury in the biopsy tissue, if thoroughly validated
3. Serologic evidence of donor-specific antibodies (HLA or other antigens)
C4d staining without evidence of rejection; all three features must be present for diagnosis10
1. Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections, or C4d>0 by IHC on paraffin sections)
2. g¼0, ptc¼0, cg¼0 (by light microscopy (LM) and by EM if available), v¼0; no TMA, no peritubular capillary basement membrane
multilayering, no acute tubular injury (in the absence of another apparent cause for this)
3. No acute cell-mediated rejection (Banff 1997 type 1A or greater) or borderline changes
1For all ABMR diagnoses, it should be specified in the report whether the lesion is C4d-positive (C4d2 or C4d3 by IF on frozen sections;
C4d>0 by IHC on paraffin sections) or without evident C4d deposition (C4d0 or C4d1 by immunofluorescence (IF) on frozen sections; C4d0
by IHC on paraffin sections).
2These lesions may be clinically acute, smoldering or subclinical. Biopsies showing two of the three features, except those with donor-
specific antibodies (DSA) and C4d without histologic abnormalities potentially related to ABMR or T cell–mediated rejection (TCMR) (C4d
staining without evidence of rejection; see footnote 10) may be designated as ‘‘suspicious’’ for acute/active ABMR.
3Recurrent/de novo glomerulonephritis should be excluded.
4It should be noted that these arterial lesions may be indicative of ABMR, TCMR or mixed ABMR/TCMR. ‘‘v’’ lesions are scored in arteries
having continuous media having two or more smooth muscle layers.
5In the presence of acute TCMR, borderline infiltrates or evidence of infection, ptc2 alone is not sufficient to define moderate
microvascular inflammation and g must be1.
6Lesions of chronic, active ABMR can range from primarily active lesions with early transplant glomerulopathy (TG) evident only by EM (cg
1a) to those with advanced TG and other chronic changes in addition to active microvascular inflammation. In the absence of evidence of
current/recent antibody interactionwith the endothelium, the term active should be omitted; in such cases DSAmay be present at the time
of biopsy or at any previous time posttransplantation.
7Includes glomerular basement membrane (GBM) duplication by EM only (cg1a) or GBM double contours by LM.
87 layers in one cortical peritubular capillary and 5 in two additional capillaries, avoiding portions cut tangentially.
9While leukocytes within the fibrotic intima favor chronic rejection, these are seen with chronic TCMR as well as chronic ABMR, and are
therefore helpful only if there is no history of TCMR. An elastic stain may be helpful as absence of elastic lamellae is more typical of chronic
rejection and multiple elastic lamellae are most typical of arteriosclerosis, although these findings are not definitive.
10The clinical significance of these findings may be quite different in grafts exposed to anti-blood-group antibodies (ABO-incompatible
allografts), where they do not appear to be injurious to the graft and may represent accommodation, and anti-HLA antibodies where more
clinical outcome data are needed.
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molecular and cellular signatures; and the pathology and
function of the allograft—are relevant, were included in the
Banff 2013 criteria, andmay subsequently affect the design
of clinical trials of patients with ABMR (16,21,30,34,36)
(Table 1).
Predictors of poor outcome related to
antibody-mediated injury
Acute and chronic ABMR are associated with poor
outcomes after kidney transplantation. Specifically, pa-
tients with acute ABMR are at greater risk for subsequent
rejection, chronic ABMR and graft loss (10,14,33,42,61).
Similarly, thosewith chronic ABMR are at increased risk for
graft loss (12,13,35,60,62,63). However, not all ABMR
phenotypes have poor outcomes, and many patients
maintain stable graft function for years after treatment of
the initial injury. We will review the independent roles
of C4d, circulating antibodies, B cells and plasma cells,
microcirculation injury/inflammation, subclinical ABMR and
novel biomarkers to predict outcomes in patients with
acute and chronic ABMR.
C4d and microvascular injury
C4d and microcirculation inflammation are independent
biomarkers of subsequent rejection, chronic ABMR and
graft loss in patientswith acute ABMR (24,33,48,62). Loupy
et al (33) demonstrated that higher increments of C4d Banff
Figure 2: Acute and chronic definitions of ABMR based on C4d positivity. ABMR, antibody-mediated rejection; ATN, acute tubular
necrosis; DSA, donor-specific antibodies; IF, immunofluorescence; IFTA, interstitial fibrosis and tubular atrophy; IHC, immunohisto-
chemistry; PTC, peritubular capillary. Reproduced with permission from Mengel et al (21).
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scores predict greater microvascular inflammation at
both 3 months and 1 year after transplant, as well as
worse TG and higher levels of class II DSA. The extent of
microvascular injury was similar between biopsies with
focal and diffuse C4d. However, the presence of microcir-
culation inflammation and class II DSA at 3 months was
related to a fourfold increased risk of chronic ABMR
independent of C4d (33). We recently demonstrated that
focal C4d staining in postreperfusion biopsies was a
significant predictor of subsequent ABMR in sensitized
patients (48). Despite the important diagnostic and
prognostic roles of C4d and microcirculation inflammation
in acute ABMR, prospective studies are required to
determine whether the treatment of isolated C4d staining
or microcirculation inflammation in patients with DSA
improves outcomes.
C4d and endothelial injury are also associated with poor
outcomes in chronic ABMR (12,13,35,60,63–65). In support
of this observation, most graft losses in the current era of
immunosuppression have evidence of chronic ABMR with
positive C4d staining (12,13,35). In the Deterioration in
Kidney Allograft Function (DeKAF) study, patients with
new-onset kidney allograft dysfunction underwent a biopsy
at a mean time of 7.3 years after transplant (60). Most
biopsies had some evidence of antibody-mediated injury
(C4d or DSA), and the risk of subsequent graft failure was
significantly increased in the presence of C4d (60). Other
studies have confirmed the association of both focal and
diffuse C4d staining in chronic ABMR with graft
loss (64,65). Microcirculation injury defined as microcircu-
lation inflammation (PTC and g) or microcirculation deterio-
ration (cg and PTC multilayering) was also an important
predictor of graft loss in late biopsies (>1 year after
transplant), independent of C4d staining (35,63). As a result,
the newBanff 2013 criteria further characterize ABMRbased
on current/recent antibody interactions with vascular endo-
thelium including C4d staining, at least moderate microvas-
cular inflammation ([gþ ptc] 2), increased expression of
ENDATs or gene expression of other validated markers of
endothelial injury in the biopsy tissue (Table 1) (30).
In summary, there is a clear and independent association
between C4d and microcirculation injury with poor out-
comes in kidney transplant recipients (KTRs) with acute or
chronic ABMR. Standardized risk stratification strategies
are needed to better define preventive and treatment
approaches for each ABMR phenotype.
Donor-specific antibodies
Preexisting (49,55) or de novo circulating antibodies (14,63)
have been shown to compromise renal allograft survival.
These antibodies may be directed against HLA or non-HLA
molecules on endothelial cells, including major histocom-
patibility complex class I-related chain A antibody (MICA),
and angiotensin type 1 receptor (37,41,66). In support of
this observation, among recipients of HLA-identical sibling
transplants, patients with no PRA had significantly higher
10-year graft survival than patients with PRA >1%,
suggesting that non-HLA immunity has an important role
in clinical transplantation and chronic graft loss (37).
In sensitized patients with preexisting anti-HLA-DSA,
8-year graft survival rates were significantly worse than in
sensitized patients without HLA-DSA or nonsensitized
patients (55). Peak HLA-DSA strength was related to the
risk of acute ABMR (49,55) and graft loss (55). Conversely,
in renal transplant recipients without preexisting DSA,
10-year graft survival was significantly lower for patients
who developed de novo HLA-DSA (14). Histopathology of
ABMR phenotype 2 could be observed in the absence of
graft dysfunction. Similar findings were reported earlier,
where patients with de novo DSA at the time of biopsy had
worse graft survival than those with preexisting DSA,
indicating that patients with ABMR phenotype 2 have
worse graft outcomes than those with ABMR phenotype
1 (63). De novo DSA are predominantly directed at class II
donor HLA mismatches and are associated with non-
adherence and cellular rejection (Figure 3) (14). Although
the reason for this is unclear, it appears that class I
antibodies are associated with early ABMR, whereas class
II antibodies are more commonly associated with late
ABMR and graft failure (14,35,48–51,63).
In summary, although DSA are important risk factors for
graft loss, the majority of patients with DSA have stable
allograft function and experience no rejection. It is therefore
important to determine the pathogenic role and specificity
of anti-class I and class II HLA and non-HLA-DSA and to
better understand the effect of de novo DSA compared
with preexisting DSA.
B cells and plasma cells
The relationship between the presence of circulating DSA
and the development of antidonor B cell responses in
allograft rejection and tolerance is currently under active
Figure 3: The natural history of phenotype 2 ABMR. ABMR,
antibody-mediated rejection; DSA, donor-specific antibodies; IFTA,
interstitial fibrosis and tubular atrophy; TG, transplant glomeru-
lopathy. Reproduced with permission from Wiebe et al (14).
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investigation (19,20). While the absence of circulating DSA
may indicate graft tolerance, it is also possible that
antibodies produced as a result of a B cell response are
not detectable because of binding/absorption by the graft
itself (20,67). To investigate donor-directed B cell re-
sponses, a recent study (19) used donor-derived fibroblasts
as targets to quantify DSA-secreting cells isolated from
peripheral blood of KTRs before and after transplantation.
Even in the absence of circulating DSA (with no evidence of
rejection), the number of DSA-secreting cells was in-
creased posttransplant in all patients, suggesting a greater
role for B cells and plasma cells in posttransplant immune
regulation than previously thought (19).
B cells may also contribute to posttransplant immune
regulation through its antigen-presenting function (20). In
addition to pathways used by other antigen-presenting
cells (APCs), B cells can present antigen via antigen
binding to the clonotypic B cell receptor (68). In turn,
B cells (unlike other APCs) undergo clonal expansion, which
may contribute to rejection by amplifying antidonor B cell
responses (20).
Subclinical ABMR
Subclinical ABMR is defined as immunohistological evi-
dence of ABMR in KTRs with normal renal allograft
function. Evidence suggests that untreated subclinical
ABMR is an important predictor of poor renal allograft
outcomes (69,70). At 1-year posttransplant, those with
subclinical ABMR at 3 months had more interstitial fibrosis
and tubular atrophy (IFTA) and TG compared with patients
who did not have subclinical ABMR at 3 months (69).
Similarly, patients with C4d-negative subclinical ABMR at
3 months (defined as PTCþg> 0) had more PTC and IFTA
and a lower GFR at 1 year relative to those without
subclinical lesions at 3 months (69). These findings were in
agreement with earlier observations that demonstrated a
strong association between subclinical rejection (70) and
chronic allograft nephropathy in 83 patients who received
HLA-incompatible renal allografts and support the indication
of protocol biopsies in sensitized recipients. Protocol
biopsies can further identify subclinical TG, which is
considered an important risk factor for chronic injury and
graft dysfunction (69,71). As a result, it is recommended
that high-risk patients (i.e. desensitized or DSA-positive/
crossmatch-negative) should be monitored by protocol
biopsies in the first 3 months after transplantation. Protocol
biopsies may also be conducted after ABMR to determine
the effectiveness of therapy and to identify prognostic
indicators of outcome (58).
Novel biomarkers
New assays and molecular tests may be considered as
diagnostic and prognostic tools in patients with ABMR.
There is evidence that ENDATs and DSA-selective tran-
scripts are indicators of active ABMR damage and worse
graft outcomes (17,34,72). The expression of these tran-
scripts in biopsiesmay provide a new tool for understanding
the pathogenesis of late kidney graft loss and ABMR, as
well as for predicting graft outcomes and defining ABMR
even in C4d-negative biopsies in patients with antibod-
ies (17,34). Differentially expressed microRNAs and their
predicted targets identified by deep sequencing may also
be candidates for further investigation to understand the
mechanism and management of kidney allograft fibrosis in
patientswith ABMR (73). The C1q assay is another test that
is designed to distinguish complement-fixing from non-
complement-fixing antibodies (56). Recent studies indicate
that a positive C1q assay for de novo DSA correlates with
acute rejection and long-term graft loss after kidney
transplantation (74–76). Other investigators have found
no significant difference in graft survival between patients
with or without preformed C1q-fixing DSA (77), suggesting
that additional studies are needed to clarify the role of this
assay in clinical transplantation. Finally, C4d-fixing luminex-
binding antibodies have been reported to predict graft
failure in heart transplantation, but the role of this assay in
kidney transplantation is being debated (78,79). In summa-
ry, while new assays with potential diagnostic and
prognostic value are being developed in the area of
ABMR, these tools need to be validated by larger studies.
Preventing ABMR
More than 20 000 patients awaiting kidney transplantation
in the United States are sensitized (typically owing to
blood transfusion, pregnancy or previous transplants) to
HLA class I and/or class II antibodies (80). Until recently,
transplantationwas routinely avoided in sensitized patients,
at the expense of prolonging waiting time for suitably HLA-
matched organs. However, with the advent of virtual
crossmatch, desensitization protocols and paired kidney
exchange (PKE) programs, timely kidney transplantation
has become a reality for many of these high-risk
patients (81,82) (Table 2). Highly sensitized patients may
be able to participate in special programs such as the
Eurotransplant Acceptable Mismatch Program (83), in
which the HLA typing of panel donors with negative
reactions is determined during screening if PRA is below
100%; alternatively, selection and crossmatching of blood
donors with a single HLA mismatch to the patient’s
phenotype can be undertaken (84). It has been argued
that implementation of these programs may lead to similar
graft survival rates to those observed in nonsensitized
patients (84).
Prevention of acute ABMR phenotype 1
Only one randomized controlled clinical trial (RCT) has been
conducted to lower allosensitization prior to transplanta-
tion (85). In this study, 101 adult patients with a PRA50%
were enrolled in a trial sponsored by the National Institutes
of Health. Patients received intravenous immunoglobulin
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(IVIG) 2 g/kg monthly for 4 months or an equivalent volume
of placebo with additional infusions at 12 and 24 months
after entry if not transplanted while on IVIG or placebo. IVIG
significantly reduced PRA levels in study subjects com-
paredwith placebo, andmore patients in the IVIG armwere
transplanted (35% vs. 17%). Seven graft failures occurred
(four IVIG, three placebo) among adherent patients with
similar 2-year graft survival rates (80% IVIG, 75% placebo).
The investigators concluded that IVIG is better than placebo
in reducing anti-HLA antibody levels and improving
transplantation rates in highly sensitized patients with
end-stage renal disease. In a follow-up study by the same
group, the combination of B cell depletion therapy and high-
dose IVIG was shown to be effective in reducing PRA from
7718% to 44 30% at the time of transplantation (86).
However, recent studies have not been able to reproduce
these data, specifically in patients with PRA>80% (87–89).
Two randomized clinical trials have examined the role of
rabbit anti-human thymocyte globulin (rATG) as induction
therapy in sensitized kidney transplants based on current or
peak PRA levels (90,91). The use of rATG was associated
with a significant reduction in the incidence of acute
rejection and improved 1-year survival, specifically in
patients who remained rejection-free, suggesting that
ATG induction may be associated with better outcomes
in sensitized patients (90,91). Compared with anti-IL-2
therapy (basiliximab), induction with rATG in moderately
sensitized KTR was associated with reduced incidence of
de novo DSA and ABMR (92). In contrast, outcomes from
the CTOT02 study, including nonsensitized adults and
children, found anti-IL-2 induction to be protective against
the development of anti-HLA antibodies; however, no
difference in allograft survival was associatedwith anti-HLA
antibody development (93,94). Although these studies
support the use of ATG and IL-2 blockade in sensitized and
low-risk patients, respectively, the effects of induction with
rATG or anti-IL-2 therapy on de novo DSA or long-term
outcomes remain largely unknown.
Nonrandomized clinical observations suggest that a combi-
nation of plasmapheresis and low-dose IVIG combinedwith
IL-2 blockade or rATG for induction has become the
standard of care for the treatment of sensitized pa-
tients (11,46,95). Using this approach, desensitization
was associated with improved patient survival compared
with chronic dialysis (95). Despite these promising findings,
long-term outcomes for crossmatch-positive living-donor
kidney transplantation are generally inferior to nonsensitized
KTRs (51,96), suggesting that better immunomodulatory
strategies are required.
Alemtuzumab, a lymphocyte-depleting, CD52-specific
monoclonal antibody, is increasingly used as induction
therapy in renal transplantation. A recent review and meta-
analysis of 10 RCTs (enrolling more than 1200 patients), as
well as studies specifically in highly sensitized patients,
concluded that alemtuzumab induction is associated with a
comparable or lower risk of biopsy-proven acute rejection
compared with rATG or IL-2 receptor antibodies (97–99). In
contrast, other studies have demonstrated potential nega-
tive effects of alemtuzumab on the regulation of humoral
immunity, including unexpectedly high rates of ABMR (100)
and high rates of circulating alloantibody and intragraft C4d
at 1-year posttransplant (100). Increased risk for ABMR
with alemtuzumabmay be partlymediated by dysregulation
of B cell activating factor (BAFF), as an increase in BAFF
mRNA expression was observed in monocytes of alemtu-
zumab-treated patients (101,102).
The anti-CD20 agent rituximab may also have utility as an
induction agent for renal transplant recipients, although its
efficacy is yet to be proven and it is not currently licensed
in this setting (103). An RCT (ClinicalTrials.gov number
Table 2: Strategies to prevent ABMR
1. Do not transplant highly sensitized patients
2. Avoid blood transfusion
3. Paired kidney exchange
4. In sensitized patients, precise characterization of their alloantibodies and exact HLA typing of the donor at the time of transplantation
5. Participation in special programs (such as the Eurotransplant Acceptable Mismatch Program)
6. Removal of DSA (plasmapheresis, immunoadsorption)
7. Direct or indirect inhibition of DSA production
a. Anti-B cell agents (rituximab1)
b. Anti-plasma cell agents (proteasome inhibitors, e.g. bortezomib1)
c. Rabbit anti-human thymocyte immunoglobulins (e.g. thymoglobulin)?
d. Costimulation blockade (e.g. belatacept)?
8. Inhibition of complement cascade (eculizumab1)
9. Intravenous immunoglobulin1
e. Neutralizing DSA: anti-idiotypic activity
f. Inhibiting complement activation by binding C3b, C4b
g. Inhibiting activation of macrophages, neutrophils by binding FcgRs
h. Apoptosis of B cells (inhibits CD19 expression)
10. Splenectomy
ABMR, antibody-mediated rejection; DSA, donor-specific antibodies; FcgRs, Fc gamma.
1These drugs are used off-label in solid organ transplantations.
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NCT00565331) presented at the 2013 American Transplant
Congress evaluated a single dose of rituximab as induction
therapy added to standard concomitant immunosuppres-
sion (i.e. tacrolimus,mycophenolatemofetil and steroids) in
patients with PRA >6% and re-transplants. The results
showed that rituximab was significantly more effective
than placebo at preventing biopsy-proven acute rejection
within the first 6 months posttransplant, though this study
did not report the effect of rituximab induction on the
incidence of ABMR (104). In a retrospective study of
patients receiving ABO-incompatible KTRs, rituximab
induction inhibited the development of de novo DSA and
reduced the rate of chronic ABMR (relative to splenectomy)
in this subset of patients (105). Further induction trials of
rituximab are ongoing (103), including the Rituximab
Induction in Renal Transplantation (ReMIND) trial (Clinical-
Trials.gov number NCT01095172).
Several observational studies have used bortezomib and
eculizumab in their desensitization protocols. Bortezomib is
a proteasome inhibitor that acts on plasma cells and is
effective in removing preformed DSAwhen combinedwith
plasmapheresis (106,107). It is also associatedwith durable
reductions in DSA and stable allograft function in de novo
DSA-positive renal transplant recipients (108). The efficacy
of the humanized anti-C5 antibody eculizumab in the
prevention of ABMR was also recently assessed in renal
transplant recipients with a positive crossmatch (109). The
incidence of ABMR was 8% with eculizumab compared
with 41% in the control group, and the rate of TG at 1 year
was also significantly lower with eculizumab (109). There is
an ongoing, multicenter, international, randomized trial
testing the role of eculizumab plus conventional treatment
(or conventional treatment alone) that may clarify its utility
(NCT00670774) (110). However, these published single-
center observations have not yet been confirmed by larger
studies, and none of these drugs is approved by the FDA for
the prevention or treatment of ABMR. Furthermore, these
protocols are associated with costs that may not be
covered by insurance.
A common approach toABMRprevention has been to avoid
transplanting highly sensitized patients. However, avoiding
transplant renders chronic dialysis the only option, with
implications for patient health and quality of life, as well as
healthcare costs. Long-term survival in posttransplant
patients has been improved considerably by desensitiza-
tion, and the enrollment of patients in special programs to
optimizematching can lead to timely transplantswith better
outcomes. A recent study examined both the efficacy and
cost-effectiveness of desensitization using IVIG and
rituximab in 146 patients who were originally DSA-positive
(PRA >80%) and transplanted with an acceptable cross-
match (111). The patient survival rate at 3 years was 96.6%
in the desensitization arm compared with 79.0% for
patients remaining on dialysis. Each patient treated with
desensitization was estimated to save the US healthcare
system $18753. These data suggest that survival and
financial gains can be achieved by a desensitization
approach; however, this was a relatively small study, and
the extent of the relative benefits of desensitization over
dialysis will ultimately be determined by drug cost.
A growing option for the prevention of ABMR in highly
sensitized patients is the use of PKE transplant programs,
such as the National Kidney Registry, the Alliance for Paired
Donation and the United Network for Organ Sharing Kidney
Paired Donations Pilot Program (112,113) (see Table 2).
Such programs enable sensitized patients with immuno-
logically incompatible living donors to be transplanted with
high-quality grafts from other living donors in similar
situations who were willing to exchange organs. Although
cost has been a concern for kidney exchange registries in
the United States, it seems that the PKE could help
participating centers avoid complex desensitization proto-
cols while improving long-term outcomes. Furthermore,
mathematical modeling predicts that an optimized match-
ing algorithm and a national PKE program would improve
outcomes and reduce healthcare costs for highly sensitized
patients (114). With the rising number of highly sensitized
patients in PKE programs, some centers combine desensi-
tization and paired exchange options.
Prevention of acute ABMR phenotype 2
Nonadherence and the choice of maintenance immuno-
suppressionmay influence the development of ABMRafter
transplant (13,14,115). For example, calcineurin inhibitor
minimization or withdrawal strategies may increase the
incidence of de novoDSA and ABMR (13,14,115). Analyses
from two prospective randomized clinical trials demon-
strated that the conversion of cyclosporine to everolimus at
3–4.5 months after transplant was associated with
significantly higher rates of de novo DSA (10.8% vs.
23%, p¼ 0.04) and ABMR (3% vs. 13%, p¼ 0.03) (116).
Whereas avoiding calcineurin-based regimens may be
advantageous in KTRs by reducing the potential risks of
nephrotoxicity and other adverse events after transplant,
the intentional or unintentional reduction of immunosup-
pression increases the risk of ABMR and graft
loss (12,13,117). Treatment with belatacept, a selective
costimulation blocker that targets CD80/CD86-CD28 inter-
action to prevent T cell activation, was associated with a
low rate of de novo DSA over 3 years of treatment in phase
III trials, although this was not an initial end point of the
studies and requires confirmation (118,119). This observa-
tion is supported by experimental data demonstrating that
belatacept inhibits primary T cell–dependent antibody
responses and the generation of DSA in primates (120).
A phase II clinical study in which conversion from a
calcineurin inhibitor-based regimen to belatacept had no
effect on the incidence of de novo DSA or ABMR despite
higher rates of cellular rejection (7% vs. 0%) (117).
In summary, notwithstanding the advent of novel immuno-
suppressive agents, the ideal regimen for the prevention of
Current Status of Antibody-Mediated Rejection
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ABMR phenotypes 1 and 2 in sensitized KTRs remains
unknown.
Treatment of ABMR
Acute ABMR
The primary aims of therapeuticmodalities for ABMR are to
remove existing antibodies and inhibit their redevelopment.
Themanagement of ABMR is challenging and is associated
with poorer outcomes compared with traditional anti-T cell
rejection therapy for pure cell-mediated rejection (121). A
recent systematic review of treatments for acute ABMR in
renal allografts found 10 388 citations but only five small
randomized and eight non-RCTs (Table 3) (122). Of these
trials, benefit was found in five studies evaluating
plasmapheresis or immunoadsorption, and small, nonran-
domized controlled studies suggested benefit from ritux-
imab or bortezomib (33,120,122,124–128,130–134). An
evaluation of a small group of patients from a randomized
trial of kidney allograft recipients suggested that immu-
noadsorption (received by five patients and compared with
the outcomes of five controls) was effective in reversing
severe C4d-positive ABMR (123). However, it is important
to note that immunoadsorption is not practiced in the
United States.
Ironically, there are no randomized controlled studies that
support the benefits of IVIG in acute ABMR, despite its
common use in this context (122). Only one randomized
controlled study has found plasmapheresis to be benefi-
cial (125); two controlled studies found no benefit (124,127)
and one found potential harm (126), indicating that the role
of plasmapheresis for the treatment of acute ABMR
remains under debate. Uncontrolled or controlled nonran-
domized studies support a role for rituximab, bortezomib,
plasmapheresis and IVIG (45,128–134). However, the
relative importance of these therapies is difficult to assess
because treatment strategies were not standardized,
doses and frequencies were not similar, and the specific
drugs were combined with other agents.
One-year results were recently reported from a phase III,
multicenter, randomized, placebo-controlled trial (RITUX
ERAH) that examined the effect of rituximab (combined
with plasmapheresis, IVIG, corticosteroids, tacrolimus and
mycophenolate mofetil) on a composite measure of graft
loss or absence of improvement of renal function at day 12,
in patients with biopsy-proven acute ABMR. ABMR
occurred after a median of 35.5 days, with no advantage
of rituximab over control for the graft loss or renal function
outcome (135).
Eculizumab was recently used for the treatment of
multidrug-resistant ABMR (136), but there are no random-
ized controlled studies to confirm the efficacy of this
expensive drug. In summary, efficacy data for the
treatment of acute ABMR are of very low quality, and
larger RCTs and dose–response studies are needed to fully
evaluate therapies in this setting (122). In the absence of
strong evidence to support consensus guidelines for the
treatment of ABMR, the Kidney Disease: Improving Global
Outcomes Transplant Work Group recommends the use of
corticosteroids, plasmapheresis, IVIG, anti-CD20 antibod-
ies and lymphocyte-depleting antibodies alone or in
combination (137) (Figure 4).
Chronic ABMR
Chronic ABMR is amore difficult condition to treat because
irreversible tissue damage has occurred in the setting of
severely compromised graft survival (138). A small-scale
retrospective study of rituximab combined with standard
maintenance immunosuppression (including prednisone,
mycophenolate mofetil and calcineurin inhibitors) in 31
patients with chronic ABMR had encouraging results, with
partial therapeutic response and an increase inmedian graft
survival in the rituximab-treated group compared with the
control group (685 days vs. 439 days, respectively). The
outcomes within the rituximab group were dichotomous,
with significantly different median survival time in res-
ponders compared with nonresponders and control
patients, though there were no pathologic parameters
that distinguished any subset of patients (139).
Clinical trials of rituximab for the treatment of chronic
ABMR are ongoing or recruiting patients (NCT00476164
[RituxiCAN-C4] in the United Kingdom andNCT00307125 in
the United States).
New directions and future perspectives
Despite the important role of ABMR in patient morbidity
and mortality after renal transplantation, our current
understanding of the pathogenesis and pathologic pheno-
types of ABMR is limited. Evidence supports an important
role for DSA in acute and chronic ABMR. However, not all
DSA detected by current assays cause injury in the allograft
and not all ABMR phenotypes cause rapid allograft failure.
Similarly, C4d has significant limitations as a biomarker of
ABMR. It will therefore be essential to determine risk
stratification strategies for DSA, C4d and ABMR pheno-
types to guide preventive and therapeutic approaches,
including plasmapheresis, IVIG and anticomplement and
anti-B/plasma cell therapies.
Treatment options for ABMR are being informed by
growing awareness of the complex role played by B cells
in acute ABMR and chronic allograft dysfunction and the
underlying biological processes. B cell lineages are now
known to havemultiple negative effects on the alloimmune
response, including antigen presentation to T cells, the
production of cytokines supporting T cell activation,
antibody production and tertiary lymphoid organ and
lymphatic vessel formation (140). Donor-specific B cells
can be detected in peripheral blood using HLA-binding
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tetramers (141,142), and these tetramers may also
represent a potential therapeutic agent to deplete donor-
specific B cells. Strategies currently used in transplantation
to deplete B cells or inhibit B cell activation are rATG,
alemtuzumab and rituximab. However, despite the short-
term depletion of B cells, alemtuzumab is associated
with altered phenotypic and functional properties of
the repopulated cells (143), which may contribute to
increased rates of ABMR (144,145). The maintenance
immunosuppressant belatacept may provide indirect inhi-
bition of B cells through costimulatory blockade of CD80
and CD86, as this disables the stimulation of CD28, a
mediator of antibody production by B cells and B cell
proliferation (146). However, belatacept is not under
evaluation as a treatment for ABMR.
Limited clinical trial evidence suggests that the proteasome
inhibitor bortezomib (which induces plasma cell apoptosis)
may be useful in combination with plasmapheresis to
reduce anti-HLA antibodies in sensitized patients and to
treat ABMR following renal transplantation (138,140,147).
Other investigational B cell-depleting therapies include
potent anti-CD20 antibodies (e.g. ofatumumab and ocreli-
zumab) and an anti-CD22 antibody (epratuzumab)
(138,140,148). Agents targeting the BAFF pathway, which
costimulates B cell survival and expansion, are also in
clinical development (e.g. atacicept and belimumab)
(140,149). The inhibition of antibody effector function is
another interesting area of research, and some promise has
already been shown by eculizumab, an anti-C5 antibody, in
the prevention and treatment of ABMR (140,149).
Many of the potential treatment options for ABMR have
been imported from other areas of medicine, without
appropriate clinical trials in kidney transplantation; hence,
there is a need for well-designed clinical trials that use
standardized and contemporary diagnostic, monitoring and
therapeutic strategies for ABMR. There are challenges in
organizing multicenter, prospective clinical trial study
groups aimed at developing agents for DSA reduction
and treatment of ABMR. There is also a bias toward
developing B cell/antibody-targeting drugs for indications
outside of transplantation (such as oncology or rheumatol-
ogy), and the FDA has highly stringent requirements for the
approval and labeling of new agents in the transplantation
arena. Before novel andmore effective treatments become
available, the close monitoring of high-risk patients and an
emphasis on adherence to well-tolerated maintenance
immunosuppressants are recommended to minimize the
risk of ABMR.
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